ReviewAsian journal of pharmaceutical sciences2020
Current multifunctional albumin-based nanoplatforms for cancer multi-mode therapy.
Review in Asian journal of pharmaceutical sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Trend of albumin nanoparticles in oncology: a bibliometric analysis of research progress and prospects.Frontiers in pharmacology · 2024Pooled it
- Harnessing albumin's natural tumor-targeting properties: nanoplatform strategies for triple-negative breast cancer therapy.Discover nano · 2026Review
- Article
- Rationalized landscape on protein-based cancer nanomedicine: Recent progress and challenges.International journal of pharmaceutics: X · 2024Review
- Article
- Dopamine-Conjugated Bovine Serum Albumin Nanoparticles Containing pH-Responsive Catechol-V(III) Coordination for In Vitro and In Vivo Drug Delivery.Biomacromolecules · 2023Article
- Human Serum Albumin Based Nanodrug Delivery Systems: Recent Advances and Future Perspective.Polymers · 2023Review
- Safety of Gold Nanoparticles: From In Vitro to In Vivo Testing Array Checklist.Pharmaceutics · 2023Article
- Protein Nanoparticles: Uniting the Power of Proteins with Engineering Design Approaches.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Review
- Interaction between DNA, Albumin and Apo-Transferrin and Iridium(III) Complexes with Phosphines Derived from Fluoroquinolones as a Potent Anticancer Drug.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Synergy of hypoxia relief and heat shock protein inhibition for phototherapy enhancement.Journal of nanobiotechnology · 2021Article
- Recent Advancements in Serum Albumin-Based Nanovehicles Toward Potential Cancer Diagnosis and Therapy.Frontiers in chemistry · 2021Review
- Nanoformulations of Ursolic Acid: A Modern Natural Anticancer Molecule.Frontiers in pharmacology · 2021Review
- Physicochemical Properties and Hematocompatibility of Layered Double Hydroxide-Based Anticancer Drug Methotrexate Delivery System.Pharmaceutics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Albumin has been widely applied for rational design of drug delivery complexes as natural carriers in cancer therapy due to its distinct advantages of biocompatibility, abundance, low toxicity and versatile property. Hence, various types of multifunctional albumin-based nanoplatforms (MAlb-NPs) that adopt multiple imaging and therapeutic techniques have been developed for cancer diagnosis and treatment. Stimuli-responsive release, including reduction-sensitive, pH-responsive, concentration-dependent and photodynamic-triggered, is important to achieve low-toxicity cancer therapy. Several types of imaging techniques can synergistically improve the effectiveness of cancer therapy. Therefore, combinational theranostic is considered to be a prospective strategy to improve treatment efficiency, minimize side effects and reduce drug resistance, which has received tremendous attentions in recent years. In this review, we highlight several stimuli-responsive albumin nanoplatforms for combinational theranostic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.